Pharmacyclics Inc. (NASDAQ:PCYC) rose $20.29 (16%) to $144 on Tuesday, gaining $1.5 billion in market cap to $10.9 billion after it said U.S. sales of oncology drug Imbruvicaibrutinib beat analyst estimates
Read the full 323 word article
User Sign In
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury